Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 receptor antagonist used to prevent thrombotic events.
## Primary Indications
* In combination with aspirin for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **History of MI:** 60 mg orally twice daily.
* **Duration of therapy:** Typically 12 months, but may be extended based on individual patient risk.
## Pediatric Dosing
* No established pediatric dosing.
## Dose Adjustments
* No dose adjustment is needed for mild to moderate hepatic impairment or in elderly patients.
* Use with caution in severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most common:** Bleeding (including fatal and intracranial), dyspnea, bradyarrhythmia.
* **Other significant:** Ventricular pauses, increased serum creatinine, increased uric acid.
## Key Drug Interactions
* **CYP3A4 inhibitors/inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor levels. Strong inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor levels.
* **CYP3A4 substrates:** Ticagrelor can inhibit CYP3A4, increasing exposure to drugs metabolized by this enzyme (e.g., simvastatin, atorvastatin).
* **Other antiplatelet agents/anticoagulants:** Increased risk of bleeding. Use with caution and consider the net clinical benefit.
* **Proton Pump Inhibitors (PPIs):** Some evidence suggests potential for reduced efficacy of ticagrelor when co-administered with certain PPIs (e.g., omeprazole).
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor renal function and uric acid levels periodically.
* Monitor heart rate for bradyarrhythmias.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effects can be reversed more quickly upon discontinuation compared to clopidogrel.
* Dyspnea is a common side effect and is usually not associated with underlying lung disease.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If discontinuation is necessary, consider a brief washout period if switching to another P2Y12 inhibitor.
* For patients undergoing PCI, ticagrelor should be initiated as soon as possible, including potentially prior to percutaneous coronary intervention (PCI) if appropriate.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for complete and up-to-date guidance.*
